Condition (MeSH)
Blepharospasm
ClinicalTrials.gov lists 41 trials for Blepharospasm or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
41 of the 41 trials are tagged with Blepharospasm itself; the rest are tagged with a narrower condition beneath it.
When did Blepharospasm trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 3 |
| 2015 | 3 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Blepharospasm trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 2/3 | 3 |
| Phase 3 | 2 |
| Phase 4 | 4 |
| Not applicable | 7 |
| Observational | 14 |
How many Blepharospasm trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 27 |
| Terminated | 5 |
| Unknown status | 8 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Blepharospasm trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 8 |
| Allergan | 4 |
| Merz Pharmaceuticals GmbH | 3 |
| Ipsen | 2 |
| Addex Pharma S.A. | 1 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Blepharospasm? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Botulinum Toxin | 2 |
| Cannabidiol | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| type A botulinum toxin | 8 |
| Wumeiwan Jiawei Fang | 1 |
| Clostridium Botulinum Toxin Type A | 1 |
| Botulinum toxin A 10U | 1 |
| Zinc Supplement | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Blepharospasm trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 7 | 1 |
| Dysphagia | 5 | 1 |
| Hip Fracture | 3 | 1 |
| Asthenia | 2 | 1 |
| Depression | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Blepharospasm? (74)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Spatiotemporal Gait Differences before and after Botulinum Toxin in People with Focal Dystonia: A Pilot Study. | Movement disorders clinical practice | 2024 | Yes |
| Visual dysfunction of superior colliculus and lateral geniculate nucleus in idiopathic blepharospasm. | Journal of the neurological sciences | 2024 | Yes |
| DystoniaBoTXNet: Novel Neural Network Biomarker of Botulinum Toxin Efficacy in Isolated Dystonia. | Annals of neurology | 2023 | Yes |
| Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact. | Medicine | 2023 | Yes |
| Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study. | Translational vision science & technology | 2023 | Yes |
Showing 5 of 74 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.